AUROBINDO PHARMA Financial Statement Analysis
|
||
|
The Revenues of AUROBINDO PHARMA have increased by 9.39% YoY .
The Earnings Per Share (EPS) of AUROBINDO PHARMA has increased by 10.82 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
AUROBINDO PHARMA Last 5 Annual Financial Results
[BOM: 524804|NSE : AUROPHARMA]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹31,724 Cr | ₹29,002 Cr | ₹24,855 Cr | ₹23,455 Cr | ₹24,775 Cr |
| Expenses | ₹25,141 Cr | ₹23,159 Cr | ₹21,137 Cr | ₹19,071 Cr | ₹19,441 Cr |
| Operating Profit (Excl OI) | ₹6,583 Cr | ₹5,843 Cr | ₹3,719 Cr | ₹4,385 Cr | ₹5,333 Cr |
| Other Income | ₹622 Cr | ₹557 Cr | ₹291 Cr | ₹323 Cr | ₹381 Cr |
| Interest | ₹457 Cr | ₹290 Cr | ₹140 Cr | ₹49 Cr | ₹74 Cr |
| Depreciation | ₹1,649 Cr | ₹1,522 Cr | ₹1,245 Cr | ₹1,127 Cr | ₹1,055 Cr |
| Profit Before Tax | ₹5,066 Cr | ₹4,380 Cr | ₹2,613 Cr | ₹3,373 Cr | ₹7,344 Cr |
| Profit After Tax | ₹3,484 Cr | ₹3,169 Cr | ₹1,928 Cr | ₹2,647 Cr | ₹5,334 Cr |
| Consolidated Net Profit | ₹3,486 Cr | ₹3,173 Cr | ₹1,928 Cr | ₹2,648 Cr | ₹5,335 Cr |
| Earnings Per Share (Rs) | ₹60.02 | ₹54.16 | ₹32.90 | ₹45.20 | ₹91.05 |
| PAT Margin (%) | 5.48 | 5.30 | 3.79 | 5.54 | 10.98 |
| ROE(%) | 11.15 | 11.18 | 7.50 | 11.38 | 27.53 |
| ROCE(%) | 14.39 | 13.76 | 9.39 | 12.71 | 30.10 |
| Total Debt/Equity(x) | 0.24 | 0.21 | 0.18 | 0.10 | 0.23 |
Key Financials |
||
| Market Cap | : | ₹ 70,578.8 Cr |
| Revenue (TTM) | : | ₹ 32,514.5 Cr |
| Net Profit(TTM) | : | ₹ 3,447.8 Cr |
| EPS (TTM) | : | ₹ 59.4 |
| P/E (TTM) | : | 20.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AUROBINDO PHARMA | 0.6% | 10.2% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 2% | 6.1% | 4.7% |
| DIVIS LABORATORIES | 0.1% | -3.5% | 8% |
| CIPLA | 1.1% | -1.1% | 2.6% |
| TORRENT PHARMACEUTICALS | -0.3% | 3.8% | 15.5% |
| DR REDDYS LABORATORIES | 2% | 4.8% | 4.8% |
| MANKIND PHARMA | -0.6% | -8.8% | -11.9% |
| ZYDUS LIFESCIENCES | 1% | -5.1% | -0.9% |
| LUPIN | 2.1% | 7.3% | 3.7% |
AUROBINDO PHARMA Revenues
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | 9.39 % |
| 5 Yr CAGR | 6.38 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹31,724 Cr | 9.39 | |
| Mar2024 | ₹29,002 Cr | 16.68 | |
| Mar2023 | ₹24,855 Cr | 5.97 | |
| Mar2022 | ₹23,455 Cr | -5.32 | |
| Mar2021 | ₹24,775 Cr | - | |
AUROBINDO PHARMA Operating Profit
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | 12.66 % |
| 5 Yr CAGR | 5.40 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹6,583 Cr | 12.66 | |
| Mar2024 | ₹5,843 Cr | 57.13 | |
| Mar2023 | ₹3,719 Cr | -15.19 | |
| Mar2022 | ₹4,385 Cr | -17.79 | |
| Mar2021 | ₹5,333 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 2.98 % |
| 5 Yr CAGR | -0.92 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 20.75% | 2.98 | |
| Mar2024 | 20.15% | 34.69 | |
| Mar2023 | 14.96% | -19.96 | |
| Mar2022 | 18.69% | -13.19 | |
| Mar2021 | 21.53% | - | |
AUROBINDO PHARMA Profit After Tax
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | 9.86 % |
| 5 Yr CAGR | -10.09 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹3,486 Cr | 9.86 | |
| Mar2024 | ₹3,173 Cr | 64.62 | |
| Mar2023 | ₹1,928 Cr | -27.21 | |
| Mar2022 | ₹2,648 Cr | -50.36 | |
| Mar2021 | ₹5,335 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 3.40 % |
| 5 Yr CAGR | -15.95 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 5.48 % | 3.40 | |
| Mar2024 | 5.3 % | 39.84 | |
| Mar2023 | 3.79 % | -31.59 | |
| Mar2022 | 5.54 % | -49.54 | |
| Mar2021 | 10.98 % | - | |
AUROBINDO PHARMA Earnings Per Share (EPS)
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | 10.82 % |
| 5 Yr CAGR | -9.89 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹60 | 10.82 | |
| Mar2024 | ₹54 | 64.62 | |
| Mar2023 | ₹33 | -27.21 | |
| Mar2022 | ₹45 | -50.36 | |
| Mar2021 | ₹91 | - | |
AUROBINDO PHARMA Return on Capital Employed (ROCE)
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | 4.58 % |
| 5 Yr CAGR | -16.85 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 14.39% | 4.58 | |
| Mar2024 | 13.76% | 46.54 | |
| Mar2023 | 9.39% | -26.12 | |
| Mar2022 | 12.71% | -57.77 | |
| Mar2021 | 30.1% | - | |
AUROBINDO PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,215.2 |
| Current MarketCap | : | ₹ 70,578.8 Cr |
| Updated EOD on | : | Dec 01,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AUROBINDO PHARMA | 0.6% |
10.2% |
|
| SENSEX | 0.9% |
0.8% |
7.1% |
AUROBINDO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE FOCUSED MIDCAP | 1.9% | 2.2% | 3.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP SELECT | 2.2% | 4.6% | 11.8% |
| NIFTY MIDCAP 50 | 1.9% | 2.3% | 11.4% |
| NIFTY PHARMA | 1.8% | 2% | 4.2% |
| NIFTY INDIA MANUFACTURING | 1.7% | -0% | 9.7% |
| NIFTY MIDCAP 100 | 1.6% | 1.5% | 9.2% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA Financials
How the annual revenues of AUROBINDO PHARMA have changed ?
The Revenues of AUROBINDO PHARMA have increased by 9.39% YoY .
How the Earnings per Share (EPS) of AUROBINDO PHARMA have changed?
The Earnings Per Share (EPS) of AUROBINDO PHARMA has increased by 10.82 % YoY .
Check out Intrinsic Value of Peers of AUROBINDO PHARMA
Compare Stock Analytics of Peers of AUROBINDO PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
